TGTX | tickerfilter.com

Fundamental analysis

40%

Profitability 25%

Dept financing 35%

Liquidity 50%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.29%

1 Month

6.59%

3 Months

25.95%

6 Months

63.48%

1 Year

215.54%

2 Year

37.17%

Key data

Stock price

$42.03

P/E Ratio

200.38

DAY RANGE

$40.95 - $42.46

EPS

-$0.75

52 WEEK RANGE

$14.87 - $43.32

52 WEEK CHANGE

$207.69

MARKET CAP

4.686 B

YIELD

N/A

SHARES OUTSTANDING

154.823 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-30-2025

BETA

1.40

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,016,922

AVERAGE 30 VOLUME

$2,858,812

Company detail

CEO: Michael S. Weiss
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: 2006

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.

TGTX - TG Therapeutics Inc